Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Silver Trust — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares Silver Trust trades at $50.98 (market cap $29.73B). The key difference: iShares Silver Trust is far larger — about 10.4× Dyne Therapeutics Inc. Common Stock's market cap, and iShares Silver Trust is more actively traded (17,545,887 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Silver Trust for 90 Days on average.
| DYN | SLV | |
|---|---|---|
Market Cap | $2.86B | $29.73B |
Volume | 3,341,579 | 17,545,887 |
Sector | Health | — |
52-Week High | $26.78 | $105.57 |
52-Week Low | $14.60 | $42.40 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SLV, the iShares Silver Trust ETF, is trading at $50.22, down 7.6% over 24 hours amid a bearish technical signal. The trust holds substantial assets of $13.41 billion with minimal liabilities, but financial metrics like P/E and revenue are unavailable. Recent news highlights pressure from rising Treasury yields and a stronger dollar, contributing to silver's sharp decline.
The outlook remains cautious due to macroeconomic headwinds and Fed policy uncertainty. While silver's industrial and monetary appeal offers long-term potential, near-term volatility and bearish technical indicators suggest limited upside. Risks include interest rate sensitivity and market sentiment shifts, requiring careful monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
